Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Development of the eating behaviour in Prader–Willi Syndrome: advances in our understanding


Prader–Willi Syndrome (PWS) is a genetically determined neurodevelopmental disorder associated with mild to moderate intellectual disability, growth and sex-hormone deficiencies and a propensity to overeat that leads to severe obesity. The PWS phenotype changes from an early disinterest in food to an increasing pre-occupation with eating and a failure of the normal satiety response to food intake. The prevention of severe obesity is primarily through strict control of access to food and it is this aspect that most limits the independence of those with PWS. This review considers the eating disorder in PWS, specifically how the as yet uncertain genetics of the syndrome and the transition from the early to the later phenotype might account for the later hyperphagia. On the basis of behavioural and imaging studies, a failure of satiety and excessive activation of neural reward pathways have both been suggested. We speculate that the overeating behaviour, consequent upon one or other of the above, could either be due to a direct effect of the PWS genotype on the feeding pathways of the hypothalamus or a consequence of prenatal changes in the regulation of genes responsible for energy balance that sets a high satiation threshold. Understanding the overeating in PWS will lead to more focused and successful management and ultimately, treatment of this life-threatening behaviour.


We review the present state of knowledge on the eating disorder and potential resultant life-threatening obesity that is associated with Prader–Willi Syndrome (PWS), a genetically determined neurodevelopmental disorder affecting 1 in 22–25 000 live births.1, 2, 3 The aims of the review are: first, to consider our understanding of the eating disorder associated with PWS primarily from a behavioural and neuroscience perspective; second, to speculate as to the possible mechanisms that might directly or indirectly link the PWS genotype to the ‘eating’ phenotype; and third, to reflect on the implications for future research and for treatment. We discuss the major theories that could account for eating behaviour and whether any of these adequately explain the complex array of characteristics that exist in PWS and fit with what we know about the pathophysiology and the genetics of the disorder. The main discussion items include considering PWS as a disorder of satiety, as well as theories of hyper-responsive rewards systems and over-sensitivity to food stimuli, as has been proposed in general obesity. Further, we consider the importance of the prenatal environment and examine the possibility that people with PWS have an altered inner physical awareness, as shown by abnormal pain responses, and how this may alter the eating behaviour.


This review has been carried out through a search of relevant articles primarily on the PubMed search engine ( using ‘eating behaviour Prader–Willi syndrome OR Prader Willi syndrome’ as the search term. As the eating behaviour is such a key feature of this rare disorder, almost all articles contain some mention of it. Therefore, articles specifically focused on eating and particularly related to behavioural aspects of eating in PWS were selected. Those papers that did not come up through the search engine but were frequently mentioned in articles were also sought through Google Scholar. Advice was also sought from experts in the field of eating behaviour in PWS and hyperphagia.

In the background we include a brief overview on the full PWS phenotype and the PWS genotype, both of which are necessary when considering neural mechanisms that might account for the eating behaviour. More detailed reviews of these aspects of the syndrome are available.4, 5 We then focus primarily on the nature of the evolving eating abnormalities in PWS: we consider the neural mechanisms that might underpin the abnormal eating behaviour; and the potential pathophysiological basis for why the regulation of eating behaviour, and therefore of energy balance, is abnormal in PWS, consequent upon the presence of the genetic abnormality.


The primary, secondary and supportive diagnostic criteria for PWS were first categorized by Holm and colleagues6 before the genetic basis for the syndrome was fully established. Since then the early and later phenotypes have been characterized and certain core features have been identified that, if absent, are invariably associated with negative genetic testing for PWS.7 At birth these include severe neonatal hypotonia and failure to thrive, and undescended testes in males. In later childhood, PWS is associated with the failure of normal secondary sexual development; a characteristic physical appearance and short stature consequent upon relative growth hormone deficiency; and the development of severe overeating behaviour. The nature and development of the eating behaviour means that if food intake is not controlled by others, obesity arises from around age 1–4 years, exacerbated by low metabolic rate due to reduced physical exertion, and also by a low lean body mass.8 These are the core features.7 In addition, other secondary and supportive features are common but their absence does not necessarily predict a negative methylation test for PWS—the established genetic diagnostic test. These characteristics include evidence of mild or moderate intellectual disability,6, 8 a high pain threshold, temperature instability and a propensity, which may continue into adult life, to certain behaviours, such as temper outbursts, repetitive and ritualistic behaviours similar to those found in autistic spectrum conditions,9, 10, 11 and severe skin picking. PWS also shows a complex psychiatric phenotype with high rates of affective disorder and the development of a psychotic illness in adult life, particularly in those with one genetic subtype of PWS.12, 13 This same sub-group (those with PWS due to uniparental disomy), in addition to repetitive and ritualistic behaviours, may also show relatively more impaired social functioning, similar to that found in people with autism spectrum disorders.14, 15

The PWS genotype

The precise genetic abnormality that, by itself, is sufficient to account for the core features of the syndrome, remains unclear. There are three genetic subtypes of PWS, the common feature being loss of expression of the paternally-expressed imprinted genes in the critical region, 15q11-q13.8 Around 70% of people with PWS have a deletion of the critical region involving the chromosome 15 of paternal origin. Approximately 20–25% have inherited both copies of chromosome 15 from the mother (maternal uniparental disomy), and 2–5% have defects of the imprinting centre (PWS-IC) at 15q11–13.16 Defects in the PWS imprinting centre can result as a failure of one of a number of factors, as discussed by Horsthemke and Wagstaff.5 The relative proportion of genetic subtypes found in a sample depend crucially on the number of older mothers in a population, as the risk of maternal uniparental disomy rises steeply with age, at least from the mid thirties.17 These genetic subtypes are indicative of PWS resulting from the absence of expression of a gene or genes whose alleles have, through evolution, become imprinted (not expressed) depending on the gender of the parent of origin. The gene(s) of relevance to PWS are normally expressed from the chromosome 15 of paternal origin with the allele(s) of maternal origin being silenced. In the case of the two main genetic subtypes (del15q11–13 of paternal origin and maternal uniparental disomy of chromosome 15), PWS arises as these genetic abnormalities result in the absence of the paternal copies of the relevant genes. In contrast, either deletions at a similar locus on chromosome 15 but affecting the chromosome 15 of maternal origin or the presence of a chromosome 15 paternal uniparental disomy, results in the phenotypically very different Angelman syndrome. In this case it is the absence of expression of a specific maternally expressed/paternally imprinted gene (Ube3a) that is causal.18 Candidate genes for PWS, on the basis of their location and being maternally imprinted, include necdin, Magel2, SNRPN, MKRN3 and snoRNA genes. Although it has been generally assumed that the wider phenotype of PWS results from the absence of expression of more than one maternally imprinted gene, a recent study of a child with PWS has shown that many of the major features are due to loss of expression of C/D box HBII-85 snoRNAs.19 Although this genetic abnormality may not account for the full phenotype of PWS, it is associated with several aspects including the abnormal eating behaviour. These snoRNAs are important in the splicing and editing of messenger RNA, but why the absence of their expression in PWS leads to overeating behaviour is uncertain. Several theories have been put forward to explain the evolutionary benefit of imprinted genes, although the precise selective advantage is unknown. In brief, genomic imprinting is thought to increase the rate of evolutionary adaptation, protection from ovarian trophoblastic disease, or occur as a result of parent–offspring conflict, as reviewed by Wilkins and Haig.20 The most studied of these theories is parent–offspring conflict or ‘kinship’ or ‘conflict’ theory. From this perspective it has been argued that any gene whose alleles have become imprinted, depending on the gender of the parent of origin, must have been subject to competing maternal/paternal selection pressures.21 In the case of the relevant gene in PWS the prediction is that the competition is for maternal resources. The allele of paternal origin would drive the use of maternal resources during pregnancy to optimize fetal growth as the paternal interest is in the survival of that particular offspring. Genes that are maternally imprinted/paternally expressed are expressed in the placenta22 and in the central control areas of the brain.23, 24 Comprehensive reviews of genomic imprinting can be found elsewhere.20, 21

Eating behaviour in PWS

Behavioural characteristics and development

The eating disorder is one of the factors, if not the factor that most affects the lives of children and adults with PWS. Controlling the hyperphagia remains a major and chronic problem for people with PWS and their families, and it severely limits independence in adult life because of the risk of life-threatening obesity. This has led to the establishment of PWS-specific homes for adults, where access to food (and usually money) is controlled. In experimental settings people with PWS have been observed to consume around three to six times more than the normal calorific intake at a given meal.25, 26 Overeating has been known to lead to stomach rupture27, 28 and individuals with PWS have been known to steal and hoard food. People with PWS have also been reported to eat inappropriate food, such as uncooked chicken, or to eat non-food items (pica).29, 30 Mortality rates in PWS have been reported as six times higher than in those with other causes for their intellectual disability31 and mortality has been estimated at around 3% per year over the lifetime.1 Obesity-related problems, such as respiratory difficulties and cardiovascular disease are the most common cause of death.32, 33 Deaths related to eating itself have also occurred including choking whilst binging, which was cause of death in 7% of people with PWS in one study.34

The developing ‘eating’ phenotype

The eating behaviour of people with PWS is traditionally characterized by two distinct phenotypic stages. The first stage, which is apparent at birth, is dominated by a lack of suck, severe hypotonia and a disinterest in food. Evidence of higher rates of hydramnios during pregnancy suggests that these problems are also of functional significance prenatally, as will be discussed later.35, 36 A recent study from our group found that 100% of the sample of children under 5 years with PWS had sucking problems from birth and 87% had at some point been tube fed.37 However, this difficulty with food intake is a transient stage and generally disappears in the earliest years of the child's life.

The later stage, which typically appears at around the ages of 2–5 years, is characterized by increasingly obsessive food-related behaviours with evidence of hyperphagia. Recent studies have examined the nature of the transition between the phenotypic stages in PWS, and suggest that there are more discrete phases within the early to late phenotype transition, and that the transition itself is gradual, rather than a distinct switch between food disinterest and food preoccupation. This change involves a period of normalization of attitudes towards eating, reported to occur around the end of the first year as assessed by Eating Code Vignettes, developed specifically for PWS.37 Unexpectedly, there is also evidence to suggest that the propensity to obesity may develop before the onset of hyperphagia with a parentally-reported increase in food interest developing after an initial escalation in body mass index.37, 38, 39

Eating behaviour in PWS varies between individuals, notable from an early age.37 Studies have shown that people with PWS do discriminate and show preferences between foods.40 PWS is associated with a high response on the ‘ritualized eating behaviour item’ from the Yale–Brown Obsessive Compulsive Scale (Y-BOCS41), and people with PWS switch less between food types than mental-age matched controls on a standard meal.42 This study also found that the bite rate correlated negatively with ordering non-food items into patterns.

Despite heterogeneity in some aspects of idiosyncratic eating behaviour, excessive food intake remains the key characteristic of PWS. Limited energy expenditure and high fat mass may contribute to rates of weight increase or difficulty in losing weight but the fault in PWS is, fundamentally, a failure to regulate energy intake. The question, then, is what level in the peripheral and central feeding pathways and in the higher centres of the brain, where conscious experiences of hunger and fullness and control of eating behaviour are represented, does the abnormality lie, and as a consequence of which pathophysiological mechanism has it arisen?

Hormonal control of appetite in PWS

In recent years there has been a drive to understand endogenous mechanisms that control appetite and eating in PWS, including gastrointestinal signals, such as pancreatic polypeptide, cholecystokinin, ghrelin and peptide YY. A full summary of hormonal control of appetite in PWS, which has been very well reviewed elsewhere,43 is not the intention of this paper. In brief, PWS presents a different endocrine picture than would be expected in general obesity. For example, adults with PWS retain insulin sensitivity and show reduced fasting levels of insulin.44, 45 Hypoinsulinemia may partially account for the hyperghrelinemia seen in PWS.46 The role of ghrelin has yet to be determined in PWS. Ghrelin levels have been reported as falling post-prandially in PWS children, suggesting that ghrelin function may be operating in childhood.47 Unpublished findings from our group show that ghrelin decreases as expected with age, although at a slower rate. Failure of circulating ghrelin levels to fail post-prandially have been reported in PWS adults48 with levels of fasting and post-prandial ghrelin elevated relative to obesity.48, 49 In a cross-sectional study in children with PWS, plasma levels of ghrelin were found to be higher than in controls, even in the early years of life, suggesting that this precedes the onset of overeating and obesity.50 Other studies however, have found normal ghrelin levels in non-obese children under 5 years of age,51 and infants52 with PWS compared with matched controls, although a subset of infants with PWS in the latter study were hyperghrelinemic and overall, the PWS group showed more heterogeneity in ghrelin levels. Reducing plasma-ghrelin level with somatostatin does not suppress appetite53 indicating that hyperghrelinemia is not the sole cause of the hyperphagia in PWS. The role of other gut hormones, such as peptide YY3−36, an anorexigenic hormone known to affect satiety,54 is not fully determined. Recently, high postprandial level of peptide YY has been shown in PWS children although fasting levels were similar to that of normal weight and obese controls.55 There is conflicting evidence of its role in adults,56 although plasma levels are thought to be appropriate for obesity (see Goldstone43). Long-term studies on the effects of age on gut hormones will determine the development of atypical regulatory systems more fully and it is likely that this will involve dysregulation in a number of systems.

Models to explain eating behaviour in PWS

Hunger vs satiety impairment

The behavioural depiction of eating in PWS suggests that individuals suffer from a continuing hunger and a consequent desperation to eat. However, an emergent literature suggests that the eating behaviour is more consistent with an abnormal satiety response, rather than an abnormal hunger.8 In line with this view, eating in PWS is more likely a consequence of not wanting to stop eating rather than always wanting to start. In one of the earliest studies to show this, 10 children with PWS took part in a test involving eating sandwich quarters. Compared with healthy weight controls, PWS children had similar initial rates of eating, but ate for a significantly longer time suggesting that there was a dysfunction of satiety signals once eating had begun.57 Subsequent studies have supported this finding.25, 26, 58, 59 Studies from our group25, 58 using an otherwise similar paradigm to Zipf and Bernston, asked 13 participants with PWS to rate their hunger, desire to eat and fullness, using a visual analogue scale. Although there was evidence of a shift in ratings in the expected direction, those with PWS had to eat on average three times more calories for the change in ratings to occur, and ratings returned towards those of the pre-meal state very shortly after food was no longer available. Reductions in ratings of hunger were found to correlate with increases in blood-glucose levels above the accepted normal range. A disturbance in satiety has also been implicated by non-decelerating eating curves seen in a PWS group compared with obese and normal weight controls.59 A study by Lindgren and colleagues, measuring meal consumption on a hidden scale, also showed that the PWS group had a slower initial eating rate than controls, further attenuating the theory that excessive hunger is the driving factor in PWS eating behaviour. Eating rate curves were accelerating or linear in 10% of the healthy weight controls and 30% of obese controls as compared with 56% of the PWS group. Moreover, the results from these behavioural studies show that the satiety response in PWS is delayed, rather than absent. In contrast, one study has shown that 75% of a group with PWS showed a decelerating eating curve.60 However, the findings of this study also show a normal eating rate, a normal reaction to food on a visual analogue scale measuring hunger and satiation and further, a failure to finish the food that they were given. The disparity between these findings and other studies is considerable, and it is likely that this study does not represent the picture in PWS and may be due to anomalies related to the experimental setting.

One of the key features of many brain imaging studies investigating eating in PWS is that most of the abnormalities described are most prominent after, rather than before eating, thus supporting the behavioural findings of irregular satiation. Recent neuroimaging studies show an irregular post-meal response with atypical brain activation post-meal,61 delayed activation of satiety centres following glucose administration62 and an abnormal or absent activation in areas associated with satiety post-meal,63 all providing support for a delayed satiation response. In a further analysis of the data from that sub-sample of people with PWS who reported changes in ratings of hunger and fullness during food intake, Hinton et al.63 found that there were changes in cortical activation from the lateral to the medial orbital frontal cortex. This observation further suggests that, whatever the cause of the abnormal satiety response, it is not absolute, rather it is impaired and delayed.

Abnormal satiety and inner physiological awareness

It is possible that the delayed satiety response is the result of a disturbance in the perception of inner physiological states. This would relate to the suggestion that people with PWS may have a problem with interoception, perception of internal sensation,64 as previously suggested (E Hinton, unpublished thesis). Interoceptive Awareness is a domain on the Eating Disorders Inventory, and is affected in obesity and anorexia nervosa.65, 66 On the Eating Disorders Inventory, Interoceptive Awareness measures the ability to differentiate sensations and feelings of hunger and satiety. The Eating Disorders Inventory has not been very widely used in PWS, as it is thought to be unable to capture the unique range of behaviours in PWS.67 General visceral awareness and interoception can be measured using a heartbeat perception task, as has been used in anorexia nervosa.66 To our knowledge, such a study has yet to be carried out in PWS.

A high pain threshold has long been noted in PWS and has recently been shown in experimental conditions.68 The authors of that study postulate that this may be due to the complex derangement of neurotransmitter balance involving the hypothalamic areas associated with PWS.42 Altered gamma-aminobutyric acidA receptor function in brain areas including the insula, a region associated with awareness of bodily states,69 which with gamma-aminobutyric acid-ergic abnormalities in other regions, may be involved in phenotypical characteristics, including altered pain sensation.70 A delayed signal reduction62 and significantly different responses to food before and after meal in the insula have also been shown.61 Any dysfunction in interoceptive awareness may be the result of the abnormal feeding problems noted in young children with PWS. In this respect, the sensation of normal feeding may never be experienced, thus the normal pattern of development of eating-related physiological awareness may be halted. Recent literature suggests that there is a stage of normalization in the eating behaviour within the transition between the early and later phenotypes.37, 38 However, it is possible that this stage of behavioural normalization is not long enough to compensate or correct for deficient physiological awareness. It is also possible that the eating behaviour during this stage of normalization is in some way qualitatively different to that of healthy peers, despite amounts eaten being perceived as normal.

Hyper-responsive reward systems

An abnormal reward response is one of the most discussed recent behavioural theories of obesity, with evidence that obese people may eat more than healthy peers because they get over and above the normal hedonic value from food. In its most potent form, the theory of reward lends support for considering eating in PWS as an addictive behaviour, with food being the substance of dependence or of abuse. In obesity in the general population, thinking of eating in terms of addiction and behavioural or neurobiological substance dependence is not a new concept; literature in this field is ever-increasing, although it remains a controversial topic.71 Addiction and substance abuse has also been reviewed in PWS in regard to eating.72 James and colleagues argue that redefining obesity as a disorder of substance dependence disorder would reduce stigmatization,73 although food is currently not accepted as a substance of abuse in the Diagnostic and Statistical Manual IV (DSM-IV-TR).74 We briefly consider the DSM-IV-TR criteria of substance dependence (as cited in Davison et al.75) for aspects of eating in PWS below:

  • tolerance: tolerance can be indicated by the substance's effects being markedly less if the normal amount is ingested. This is clearly shown by the large amount of food required for any degree of satiation.25

  • withdrawal: irritability and temper tantrums often result from being denied food.

  • substance taken for a longer time or greater amount than intended: difficulty in controlling food intake in PWS is common and often access has to be severely limited.

  • negative consequences: overeating continues unless restraints are in place despite negative consequences on health, employment and family life.

  • putting off or neglecting activities: eating often takes priority over tasks at work or at home.

  • spending significant time or emotional energy in obtaining: significant efforts in acquiring foods, concealing eating or planning to obtain foods are common.

  • desire to reduce or control use: many people with PWS, and certainly their families, attempt daily to cut down the overeating behaviour (although it is thought that many people with PWS will talk of their desire to cut down without actually trying to do so themselves).

Neuroimaging studies in PWS have shown a hyper-responsive reward circuit related to food.76 A delayed signal reduction after glucose ingestion has been shown in PWS in the hypothalamus, the ventromedial prefrontal cortex, insula and the nucleus accumbens of the ventral striatum,62 an area long established as a ‘pleasure centre’ and one involved in food preference.77 Further studies show greater reward circuit activation in response to high-calorie foods compared with intelligence quotient-matched controls.78 Recently, it was shown that the food motivation network is activated before and after meal to a larger extent in deletion subtypes than in UPD, suggesting a specific genetic effect on reward systems.79 Further to imaging studies, there is recent suggestion that aberrant mesolimbic dopamine signalling, a key neurotransmitter implicated in addiction, may be involved in PWS (as well as in bulimia nervosa and binge eating disorder).80 The case for addiction theories or at least of an abnormally high reward attachment with food in PWS is compelling. Anecdotal reports show that people with PWS who live in specialized residential homes often ‘swap’ their preoccupation with food for a preoccupation with smoking and cigarettes when food is not available, suggesting an overarching need to stimulate neural reward systems, preferably with food, but if not, with nicotine. Considering over eating in PWS as a disorder of addiction may open the possibility of exploring the efficacy of behavioural or pharmacological treatments currently available for substance abusers. It would also help to underline the importance of avoiding food cues, to which people with PWS are susceptible.81

Pathophysiological mechanisms

With the application of functional scanning technologies it has been possible to move from behavioural observations to investigating underlying neural responses to food intake and how these correlate with observed behaviours and with ratings of hunger and satiation. Thus, in the context of these above theories, the question that arises is how can this be explained given what is known about the PWS genotype, early development in PWS and the peripheral and hypothalamic feeding pathways in PWS? We propose two models that we speculate could account for eating behaviour. The first is that there is a direct connection between the absence of expression of the ‘PWS gene’ and a disruption in the feeding pathways of the hypothalamus. PWS should, therefore, be seen as a consequence of abnormal hypothalamic development resulting in the many aspects of the phenotype that are suggestive of hypothalamic dysfunction (feeding irregularities, sex and growth hormone regulation and temperature instability). The second is that abnormal placental function of fetal origin results in abnormal energy transfer in utero and a resultant compensatory mechanism in other systems in fetal tissue that then sets an abnormally high ‘satiety threshold’—this becomes apparent once the infant is required to control his/her own energy balance. We examine each of these in turn.

Eating behaviour as a direct consequence of a genetically determined deficit in a hypothalamic feeding pathway

PWS clearly results in hypothalamic dysfunction. As described above many of the phenotypic characteristics of the syndrome are likely manifestations of such dysfunction. The question is whether the eating disorder in particular can be traced directly back to a genetic abnormality in the hypothalamic feeding pathways. Genetic causes of non-PWS extreme obesity and overeating continue to be identified, showing a genetic basis for direct disruption in the peripheral or hypothalamic feeding pathways. Starting with the periphery and working towards the hypothalamus: leptin deficiency, leptin receptor abnormalities, melanocortin-4 receptor and pro-opiomelanocortin abnormalities are among those that have been described.82 Melanocortin-4 receptor abnormalities are now the single most prevalent obesity syndrome, overtaking that previously claimed by PWS.83 Recently, a form of obesity has also been associated with deletions on chromosome 16p11.2.84 None of the neurotransmitters or their receptors identified so far that are known to be involved in these pathways have been found to be localized at 15q11-13 and, therefore, candidate genes for the eating disorder in PWS. It is possible that other genes involved in the feeding pathways are implicated in PWS, but not other forms of obesity. Histochemical and molecular studies of hypothalamic tissue obtained at post-mortem from people with PWS have been difficult to undertake due to problems obtaining the necessary tissue in the ideal condition. One particular finding, that there are reduced numbers of oxytocin-containing cells in the paraventricular nucleus of the hypothalamus, has been proposed as a possible cause of the eating behaviour.85 Given that the gene for oxytocin is located on chromosome 20, this deficit must, however, be an indirect consequence of the PWS genotype. Within the broader phenotype of PWS, central oxytocin deficiency may be of relevance,86 for example, in explaining anxiety and attachment behaviours, although whether it accounts for the eating disorder is open for question. Levels of neuropeptide Y and agouti-related polypeptide in the paraventricular nucleus have also been studied and found to be normal. At present, therefore, no direct or indirect link has been established between a candidate imprinted gene located at 15q11-13 and the feeding pathways of the hypothalamus.

Prenatal Problems and the ‘Thrifty Phenotype’

A number of fetal abnormalities have been described in PWS, including reduced fetal movement, evidence of abnormal fetal growth, abnormal fetal position at birth and severe hypotonia that is central in origin.8 Infants with PWS subsequently show poor suck and weight gain, with tube feeding often necessary. Two studies examining the early years of PWS indicate that abnormalities seen in PWS may be prenatal in origin.35, 36 Common findings between these studies included, small gestational weight, increased number of Caesarean sections, increased rate of polyhydramnios, suckling deficit and hypotonia. A low birth weight as opposed to length, found in these studies and others,37 has been interpreted as a prenatal deficiency in nutrition rather than in growth.36 This has been hypothesized as being due to placental abnormalities, which are yet to be investigated in full.

One theory, which can explain an early failure to thrive and reduced neonatal weight, is that the genetic defect in PWS leads to fetal starvation and consequently, abnormal brain development, perhaps as a result of inadequate placental function.87 We have suggested that the entire PWS phenotype could, therefore, be the result of a monogenic abnormality, and the failure of expression of the paternal allele of a maternally imprinted gene that is involved in energy homeostasis.87 Much work has been done in other fields to correlate fetal nutritional abnormalities and subsequent adult-onset disorders. The Barker hypothesis, otherwise known as the ‘Thrifty Phenotype hypothesis’,88 has been proposed to explain the relationship between impaired fetal growth and the risk of developing abnormal glucose tolerance89 and metabolic syndrome.90 More recently, nutritional problems in the womb and in early life, leading to under-nourished neonates, have been associated with a higher rate of many diseases, including obesity.91 We speculate that in PWS, the Barker hypothesis could be extended to explain the high threshold and delay in satiety resulting from fetal starvation.

The fetal starvation theory postulated by our group is part of a larger hypothesis that PWS can be conceptualized as a disorder of starvation that presents as obesity in a food-rich environment. As there is no enduring sense of satiety due to failed neurological mechanisms, the body may incorrectly perceive itself to be in a state of starvation and to eat whenever food is available, which coincides with the theories of impaired interoception. In support of PWS as a model for starvation, there are metabolic commonalities between anorexia nervosa and PWS, including reports of elevated levels of ghrelin.92 There is much to suggest that ghrelin levels at birth are normal, as discussed earlier. Other similarities with anorexia include reduced metabolic rate and reduced gonadotropin release.93 Studies with mouse models of PWS also provide support for early starvation theory with neonatal failure to thrive and the later hyperphagic phenotype resultant from a failure of compensatory mechanisms,94, 95 although the latter study did not find problems with placenta of the mice. We have suggested that in PWS patients, fetal starvation may be related to the food intake reducing hormone leptin in the placenta.87 Leptin and its receptors are widely expressed in the placenta and may be related to fetal size, fetal tissue development and short- and long-term energy control.96 Leptin is a key anorexigenic hormone fundamental to the energy homeostasis97 and in the interplay of gut, vagal and brain regions regulating satiation.98 Congenital leptin deficiency results in PWS-like symptoms, including hyperphagia and hypogonadism, which is reversed, often dramatically, by recombinant leptin therapy.99, 100 At first glance, it may be assumed that leptin therapy would be of use in treating PWS. However, in PWS, leptin levels are as expected for fat mass and leptin genes are located on chromosome 7. Functional neuroimaging studies of people with congenital leptin deficiency have shown that leptin modulates neural activity in circuits involving food intake to reduce the perception of food reward and increase response to satiety signals.101 Therefore, if people with PWS are in fact insensitive to leptin, as we predict that they are, then it follows that their reward circuitry in response to food may be hyper-responsive as is shown in imaging studies. Together, the evidence suggests that people with PWS are insensitive to leptin, possibly because of an altered feedback mechanism as a result of early metabolic abnormalities and fetal starvation.

Treatment implications

To date, attempts to curb the life-threatening hyperphagia have been unsuccessful. Appetite-reducing drugs used in simple obesity have not shown wide-spread improvements,102 and bariatric procedures have been associated with severe complications.103, 104 Growth hormone treatment has been shown to improve the fat-muscle mass ratio,105 and may help to avoid the obesity for the younger generations of people with PWS, but has no effect on eating behaviour. As parents are now aware of the implications of PWS from very early on in their child's life, eating management advice and discipline may help delay problems in future. However, at present, the only available control for hyperphagia for most people with PWS is close mentoring by carers and life-long restricted access to food, with food cupboards and refrigerators often being locked.29 Understanding the characteristics and development of hyperphagia is key to improving its management and, ultimately, its prevention through effective treatments. However, from a positive perspective, studies of neurodevelopmental disorders in general have increasingly focused on symptomology and how treatment might address one particular aspect of the phenotype (for example as in fragile-X syndrome and tuberous sclerosis). The same is clearly true in PWS. Growth hormone treatment changes the physical phenotype and corrects short stature, treatments are available for the associated psychiatric disorders,106 and more sophisticated models of understanding of the behavioural problems have been developed.107 Considering the eating disorder as a stand-alone aspect of PWS will likely lead to similar advances.


We have reviewed theories that may help to elucidate the eating behaviour in PWS. In summary we have considered overeating in PWS as a problem of satiety as opposed to hunger; the role of inner physiological awareness and its potential effects on feelings of hunger and satiation; hyper-responsive reward systems and food as a substance of abuse; the direct consequence of genetics on the hypothalamic feeding pathway; and the role of the prenatal environment. The eating behaviour in PWS is complex, and we note that these theoretical models do not have to be regarded as mutually exclusive. We propose that all of the models described can in some way be encompassed by conceptualizing PWS as a model for starvation.87 In this case, it is hypothesized that the genetic abnormality could involve a gene regulating metabolism, which may result in an inadequate placenta and pre-setting of thresholds of anorexigenic hormones, such as leptin. The genetic abnormality may be the cause of fetal malnourishment or fetal starvation, leading to neonatal failure to thrive and problems with feeding. Ghrelin may be involved in the instigation of the binging and hyperphagic stage, and later development of atypical reward circuitry in response to food may be the result of altered pathways generated in the early binging stages in childhood, combined with insensitivity to satiation cues, such as leptin levels. Examining reward pathways by neural imaging in response to food in younger children, for example, may elucidate the development of the hyper-responsive circuitry.

Studies in the past years have greatly increased our knowledge about the neural, endocrinological and behavioural aspects of PWS. Reviewing behavioural advances, further strengthened by neural data, will help define and focus how PWS is conceptualized, for example, to think of PWS as a disorder of satiety rather than hunger, and to acknowledge the role of reward systems. Much is yet to be discovered about the behavioural, neural, genetic and endocrinological aspects of the syndrome, and a multi-disciplinary approach will be necessary in considering treatment or management strategies. It is hoped that evaluating the theories to explain PWS will aid the direction of future studies.


  1. 1

    Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H . Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792–798.

    CAS  Article  Google Scholar 

  2. 2

    Smith A, Egan J, Ridley G, Haan E, Montgomery P, Williams K et al. Birth prevalence of Prader-Willi syndrome in Australia. Arch Dis Child 2003; 88: 263–264.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3

    Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004; 12: 238–240.

    CAS  PubMed  Google Scholar 

  4. 4

    Goldstone AP . Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004; 15: 12–20.

    CAS  Google Scholar 

  5. 5

    Horsthemke B, Wagstaff J . Mechanisms of imprinting of the Prader-Willi/Angelman region. Am J Med Genet A 2008; 146A: 2041–2052.

    CAS  PubMed  Google Scholar 

  6. 6

    Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993; 91: 398–402.

    CAS  PubMed  Google Scholar 

  7. 7

    Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H . Relationship between clinical and genetic diagnosis of Prader-Willi syndrome. J Med Genet 2002; 39: 926–932.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8

    Cassidy SB, Driscoll DJ . Prader-Willi syndrome. Eur J Hum Genet 2009; 17: 3–13.

    CAS  PubMed  Google Scholar 

  9. 9

    Clarke DJ, Boer H, Whittington J, Holland A, Butler J, Webb T . Prader-Willi syndrome, compulsive and ritualistic behaviours: the first population-based survey. Br J Psychiatry 2002; 180: 358–362.

    CAS  PubMed  Google Scholar 

  10. 10

    Holland AJ, Whittington JE, Butler J, Webb T, Boer H, Clarke D . Behavioural phenotypes associated with specific genetic disorders: evidence from a population-based study of people with Prader-Willi syndrome. Psychol Med 2003; 33: 141–153.

    CAS  PubMed  Google Scholar 

  11. 11

    Greaves N, Prince E, Evans DW, Charman T . Repetitive and ritualistic behaviour in children with Prader-Willi syndrome and children with autism. J Intellect Disabil Res 2006; 50: 92–100.

    CAS  PubMed  Google Scholar 

  12. 12

    Clarke DJ . Prader-Willi syndrome and psychoses. Br J Psychiatry 1993; 163: 680–684.

    CAS  PubMed  Google Scholar 

  13. 13

    Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H et al. The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 2008; 38: 1505–1514.

    CAS  PubMed  Google Scholar 

  14. 14

    Veltman MW, Thompson RJ, Roberts SE, Thomas NS, Whittington J, Bolton PF . Prader-Willi syndrome--a study comparing deletion and uniparental disomy cases with reference to autism spectrum disorders. Eur Child Adolesc Psychiatry 2004; 13: 42–50.

    PubMed  Google Scholar 

  15. 15

    Dimitropoulos A, Schultz RT . Autistic-like symptomatology in Prader-Willi syndrome: a review of recent findings. Curr Psychiatry Rep 2007; 9: 159–164.

    PubMed  Google Scholar 

  16. 16

    Cassidy SB . Prader-Willi syndrome. J Med Genet 1997; 34: 917–923.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17

    Whittington JE, Butler JV, Holland AJ . Changing rates of genetic subtypes of Prader-Willi syndrome in the UK. Eur J Hum Genet 2007; 15: 127–130.

    CAS  PubMed  Google Scholar 

  18. 18

    Clayton-Smith J, Laan L . Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003; 40: 87–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008; 40: 719–721.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20

    Wilkins JF, Haig D . What good is genomic imprinting: the function of parent-specific gene expression. Nat Rev Genet 2003; 4: 359–368.

    CAS  PubMed  Google Scholar 

  21. 21

    Haig D, Wharton R . Prader-Willi syndrome and the evolution of human childhood. Am J Hum Biol 2003; 15: 320–329.

    PubMed  Google Scholar 

  22. 22

    Bressan FF, De Bem TH, Perecin F, Lopes FL, Ambrosio CE, Meirelles FV et al. Unearthing the roles of imprinted genes in the placenta. Placenta 2009; 30: 823–834.

    CAS  PubMed  Google Scholar 

  23. 23

    Keverne EB . Genomic imprinting and the maternal brain. Prog Brain Res 2001; 133: 279–285.

    CAS  PubMed  Google Scholar 

  24. 24

    Davies CJ . Why is the fetal allograft not rejected? J Anim Sci 2007; 85: E32–E35.

    CAS  PubMed  Google Scholar 

  25. 25

    Holland AJ, Treasure J, Coskeran P, Dallow J, Milton N, Hillhouse E . Measurement of excessive appetite and metabolic changes in Prader-Willi syndrome. Int J Obes Relat Metab Disord 1993; 17: 527–532.

    CAS  PubMed  Google Scholar 

  26. 26

    Fieldstone A, Zipf WB, Sarter MF, Berntson GG . Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes Res 1998; 6: 29–33.

    CAS  PubMed  Google Scholar 

  27. 27

    Wharton RH, Wang T, Graeme-Cook F, Briggs S, Cole RE . Acute idiopathic gastric dilation with gastric necrosis in individuals with Prader-Willi syndrome. Am J Med Genet 1997; 73: 437–441.

    CAS  PubMed  Google Scholar 

  28. 28

    Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2007; 45: 272–274.

    PubMed  PubMed Central  Google Scholar 

  29. 29

    Hoffman CJ, Aultman D, Pipes P . A nutrition survey of and recommendations for individuals with Prader-Willi syndrome who live in group homes. J Am Diet Assoc 1992; 92: 823–830, 833.

    CAS  PubMed  Google Scholar 

  30. 30

    Duker PC, Nielen M . The use of negative practice for the control of pica behavior. J Behav Ther Exp Psychiatry 1993; 24: 249–253.

    CAS  PubMed  Google Scholar 

  31. 31

    Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Taffe J . Mortality in Prader-Willi syndrome. Am J Ment Retard 2006; 111: 193–198.

    PubMed  PubMed Central  Google Scholar 

  32. 32

    Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP . Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A 2004; 124A: 333–338.

    PubMed  Google Scholar 

  33. 33

    Tauber M, Diene G, Molinas C, Hebert M . Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A 2008; 146: 881–887.

    Google Scholar 

  34. 34

    Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N et al. Deaths due to choking in Prader-Willi syndrome. Am J Med Genet A 2007; 143: 484–487.

    PubMed Central  Google Scholar 

  35. 35

    Dudley O, Muscatelli F . Clinical evidence of intrauterine disturbance in Prader-Willi syndrome, a genetically imprinted neurodevelopmental disorder. Early Hum Dev 2007; 83: 471–478.

    PubMed  Google Scholar 

  36. 36

    Whittington JE, Butler JV, Holland AJ . Pre-, peri- and postnatal complications in Prader-Willi syndrome in a UK sample. Early Hum Dev 2008; 84: 331–336.

    CAS  PubMed  Google Scholar 

  37. 37

    Butler JV, Whittington JE, Holland AJ, McAllister CJ, Goldstone AP . The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood. Dev Med Child Neuro l 2010; 52: e88–e93.

    Google Scholar 

  38. 38

    McCune H . Driscoll DJ Prader-Willi Syndrome. In: Efvall SW, Efvall VK (eds). Paediatric nutrition in chronic diseases and developmental disorders, 2nd edn. Oxford University Press: New York, NY, USA, 2005. pp 128–132.

    Google Scholar 

  39. 39

    Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M . Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93: 4183–4197.

    CAS  PubMed  Google Scholar 

  40. 40

    Hinton EC, Holland AJ, Gellatly MS, Soni S, Owen AM . An investigation into food preferences and the neural basis of food-related incentive motivation in Prader-Willi syndrome. J Intellect Disabil Res 2006; 50: 633–642.

    CAS  Google Scholar 

  41. 41

    Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006–1011.

    CAS  PubMed  Google Scholar 

  42. 42

    Dimitropoulos A, Feurer ID, Roof E, Stone W, Butler MG, Sutcliffe J et al. Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi syndrome. Ment Retard Dev Disabil Res Rev 2000; 6: 125–130.

    CAS  PubMed  Google Scholar 

  43. 43

    Goldstone AP . The hypothalamus, hormones, and hunger: alterations in human obesity and illness. Prog Brain Res 2006; 153: 57–73.

    CAS  PubMed  Google Scholar 

  44. 44

    Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A . Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998; 157: 890–893.

    CAS  PubMed  Google Scholar 

  45. 45

    Schuster DP, Osei K, Zipf WB . Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996; 45: 1514–1520.

    CAS  PubMed  Google Scholar 

  46. 46

    Goldstone AP, Patterson M, Kalingag N, Ghatei MA, Brynes AE, Bloom SR et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005; 90: 2681–2690.

    CAS  PubMed  Google Scholar 

  47. 47

    Bizzarri C, Rigamonti AE, Giannone G, Berardinelli R, Cella SG, Cappa M et al. Maintenance of a normal meal-induced decrease in plasma ghrelin levels in children with Prader-Willi syndrome. Horm Metab Res 2004; 36: 164–169.

    CAS  PubMed  Google Scholar 

  48. 48

    DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461–5464.

    CAS  PubMed  Google Scholar 

  49. 49

    Haqq AM, Farooqi IS, O’Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88: 174–178.

    CAS  PubMed  Google Scholar 

  50. 50

    Feigerlova E, Diene G, Conte-Auriol F, Molinas C, Gennero I, Salles JP et al. Hyperghrelinemia precedes obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93: 2800–2805.

    CAS  PubMed  Google Scholar 

  51. 51

    Erdie-Lalena CR, Holm VA, Kelly PC, Frayo RS, Cummings DE . Ghrelin levels in young children with Prader-Willi syndrome. J Pediatr 2006; 149: 199–204.

    CAS  PubMed  Google Scholar 

  52. 52

    Haqq AM, Grambow SC, Muehlbauer M, Newgard CB, Svetkey LP, Carrel AL et al. Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. Clin Endocrinol (Oxf) 2008; 69: 911–920.

    CAS  Google Scholar 

  53. 53

    Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA, Goldstone AP . Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2004; 89: 4162–4165.

    CAS  Google Scholar 

  54. 54

    Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650–654.

    CAS  Google Scholar 

  55. 55

    Bizzarri C, Rigamonti AE, Luce A, Cappa M, Cella SG, Berini J et al. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur J Endocrinol 2010; 162: 499–505.

    CAS  PubMed  Google Scholar 

  56. 56

    Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Gonzalez-Clemente JM, Potau N, Berlanga E et al. A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin Endocrinol (Oxf) 2007; 66: 198–204.

    CAS  Google Scholar 

  57. 57

    Zipf WB, Berntson GG . Characteristics of abnormal food-intake patterns in children with Prader-Willi syndrome and study of effects of naloxone. Am J Clin Nutr 1987; 46: 277–281.

    CAS  Google Scholar 

  58. 58

    Holland AJ, Treasure J, Coskeran P, Dallow J . Characteristics of the eating disorder in Prader-Willi syndrome: implications for treatment. J Intellect Disabil Res 1995; 39 (Part 5): 373–381.

    PubMed  Google Scholar 

  59. 59

    Lindgren AC, Barkeling B, Hagg A, Ritzen EM, Marcus C, Rossner S . Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. J Pediatr 2000; 137: 50–55.

    CAS  PubMed  Google Scholar 

  60. 60

    Hoybye C, Barkeling B, Naslund E, Thoren M, Hellstrom PM . Eating behavior and gastric emptying in adults with Prader-Willi syndrome. Ann Nutr Metab 2007; 51: 264–269.

    CAS  PubMed  Google Scholar 

  61. 61

    Holsen LM, Zarcone JR, Brooks WM, Butler MG, Thompson TI, Ahluwalia JS et al. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2006; 14: 1028–1037.

    Google Scholar 

  62. 62

    Shapira NA, Lessig MC, He AG, James GA, Driscoll DJ, Liu Y . Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. J Neurol Neurosurg Psychiatry 2005; 76: 260–262.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Hinton EC, Holland AJ, Gellatly MS, Soni S, Patterson M, Ghatei MA et al. Neural representations of hunger and satiety in Prader-Willi syndrome. Int J Obes (Lond) 2006; 30: 313–321.

    CAS  Google Scholar 

  64. 64

    Craig AD . How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002; 3: 655–666.

    CAS  PubMed  Google Scholar 

  65. 65

    Garner DM, Garfinkel PE, Moldofsky H . Perceptual experiences in anorexia nervosa and obesity. Can Psychiatr Assoc J 1978; 23: 249–263.

    CAS  PubMed  Google Scholar 

  66. 66

    Pollatos O, Kurz AL, Albrecht J, Schreder T, Kleemann AM, Schopf V et al. Reduced perception of bodily signals in anorexia nervosa. Eat Behav 2008; 9: 381–388.

    PubMed  Google Scholar 

  67. 67

    Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E . Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2007; 15: 1816–1826.

    Google Scholar 

  68. 68

    Priano L, Miscio G, Grugni G, Milano E, Baudo S, Sellitti L et al. On the origin of sensory impairment and altered pain perception in Prader-Willi syndrome: a neurophysiological study. Eur J Pain 2009; 13: 829–835.

    PubMed  Google Scholar 

  69. 69

    Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ . Neural systems supporting interoceptive awareness. Nat Neurosci 2004; 7: 189–195.

    CAS  PubMed  Google Scholar 

  70. 70

    Lucignani G, Panzacchi A, Bosio L, Moresco RM, Ravasi L, Coppa I et al. GABA A receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Neuroimage 2004; 22: 22–28.

    Google Scholar 

  71. 71

    Dagher A . The neurobiology of appetite: hunger as addiction. Int J Obes (Lond) 2009; 33 (Suppl 2): S30–S33.

    Google Scholar 

  72. 72

    von Deneen KM, Gold MS, Liu Y . Food Addiction and Cues in Prader Willi Syndrome. J Addict Med 2009; 3: 1–7.

    Google Scholar 

  73. 73

    James GA, Gold MS, Liu Y . Interaction of satiety and reward response to food stimulation. J Addict Dis 2004; 23: 23–37.

    PubMed  Google Scholar 

  74. 74

    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision, Washington, DC, American Psychiatric Association, 2000.

  75. 75

    Davison GC, Neale JM, Kring AM (eds). Abnormal psychology 9th edn. Wiley: USA, 2004.

    Google Scholar 

  76. 76

    Miller JL, James GA, Goldstone AP, Couch JA, He G, Driscoll DJ et al. Enhanced activation of reward mediating prefrontal regions in response to food stimuli in Prader-Willi syndrome. J Neurol Neurosurg Psychiatry 2007; 78: 615–619.

    Google Scholar 

  77. 77

    Berthoud HR . Neural control of appetite: cross-talk between homeostatic and non-homeostatic systems. Appetite 2004; 43: 315–317.

    Google Scholar 

  78. 78

    Dimitropoulos A, Schultz RT . Food-related neural circuitry in Prader-Willi syndrome: response to high- versus low-calorie foods. J Autism Dev Disord 2008; 38: 1642–1653.

    Google Scholar 

  79. 79

    Holsen LM, Zarcone JR, Chambers R, Butler MG, Bittel DC, Brooks WM et al. Genetic subtype differences in neural circuitry of food motivation in Prader-Willi syndrome. Int J Obes (Lond) 2009; 33: 273–283.

    CAS  Google Scholar 

  80. 80

    Lutter M, Nestler EJ . Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 2009; 139: 629–632.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. 81

    Hinton EC, Isles AR, Williams NM, Parkinson JA . Excessive appetitive arousal in Prader-Willi syndrome. Appetite 2010; 54: 225–228.

    CAS  PubMed  Google Scholar 

  82. 82

    O’Rahilly S, Farooqi IS . Human obesity as a heritable disorder of the central control of energy balance. Int J Obes (Lond) 2008; 32 (Suppl 7): S55–S61.

    Google Scholar 

  83. 83

    Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106: 271–279.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84

    Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature 2010; 463: 671–675.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85

    Swaab DF, Purba JS, Hofman MA . Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80: 573–579.

    CAS  PubMed  Google Scholar 

  86. 86

    Heinrichs M, Domes G . Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 2008; 170: 337–350.

    CAS  PubMed  Google Scholar 

  87. 87

    Holland A, Whittington J, Hinton E . The paradox of Prader-Willi syndrome: a genetic model of starvation. Lancet 2003; 362: 989–991.

    CAS  PubMed  Google Scholar 

  88. 88

    Hales CN, Barker DJ . Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595–601.

    CAS  Google Scholar 

  89. 89

    Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991; 303: 1019–1022.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. 90

    Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM . Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36: 62–67.

    CAS  Google Scholar 

  91. 91

    Barker DJ . Obesity and early life. Obes Rev 2007; 8: (Suppl 1): 45-49.

    Google Scholar 

  92. 92

    Tanaka M, Naruo T, Yasuhara D, Tatebe Y, Nagai N, Shiiya T et al. Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology 2003; 28: 829–835.

    CAS  PubMed  Google Scholar 

  93. 93

    Whittington JE, Holland AJ (eds). Prader-Willi Syndrome: Development and Manifestations. Cambridge University Press: Cambridge, UK, 2004.

    Google Scholar 

  94. 94

    Skryabin BV, Gubar LV, Seeger B, Pfeiffer J, Handel S, Robeck T et al. Deletion of the MBII-85 snoRNA gene cluster in mice results in postnatal growth retardation. PLoS Genet 2007; 3: e235.

    PubMed  PubMed Central  Google Scholar 

  95. 95

    Stefan M, Claiborn KC, Stasiek E, Chai JH, Ohta T, Longnecker R et al. Genetic mapping of putative Chrna7 and Luzp2 neuronal transcriptional enhancers due to impact of a transgene-insertion and 6.8 Mb deletion in a mouse model of Prader-Willi and Angelman syndromes. BMC Genomics 2005; 6: 157.

    PubMed  PubMed Central  Google Scholar 

  96. 96

    Forhead AJ, Fowden AL . The hungry fetus? Role of leptin as a nutritional signal before birth. J Physiol 2009; 587: 1145–1152.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. 97

    Farooqi IS, O’Rahilly S . Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S–984S.

    CAS  PubMed  Google Scholar 

  98. 98

    Berthoud HR . Vagal and hormonal gut-brain communication: from satiation to satisfaction. Neurogastroenterol Motil 2008; 20 (Suppl 1): 64–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99

    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879–884.

    CAS  Google Scholar 

  100. 100

    Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093–1103.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101

    Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC . Leptin regulates striatal regions and human eating behavior. Science 2007; 317: 1355.

    CAS  Google Scholar 

  102. 102

    Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ . Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004; 109: 301–309.

    PubMed  Google Scholar 

  103. 103

    Papavramidis ST, Kotidis EV, Gamvros O . Prader-Willi syndrome-associated obesity treated by biliopancreatic diversion with duodenal switch. Case report and literature review. J Pediatr Surg 2006; 41: 1153–1158.

    PubMed  Google Scholar 

  104. 104

    Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W . Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2008; 46: 80–83.

    CAS  PubMed  Google Scholar 

  105. 105

    Eiholzer U, L’Allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C . Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004; 144: 753–758.

    CAS  PubMed  Google Scholar 

  106. 106

    Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 2007; 51: 32–42.

    CAS  Google Scholar 

  107. 107

    Woodcock KA, Oliver C, Humphreys GW . A specific pathway can be identified between genetic characteristics and behaviour profiles in Prader-Willi syndrome via cognitive, environmental and physiological mechanisms. J Intellect Disabil Res 2009; 53: 493–500.

    CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to C J McAllister.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McAllister, C., Whittington, J. & Holland, A. Development of the eating behaviour in Prader–Willi Syndrome: advances in our understanding. Int J Obes 35, 188–197 (2011).

Download citation


  • Prader–Willi syndrome
  • hyperphagia
  • eating
  • behaviour
  • satiety

Further reading


Quick links